Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-32729463 vs Moxifloxacin in Hospitalized CABP
NCT01198626Phase 2Terminated
- Sponsor
- Furiex Pharmaceuticals
- Start
- Oct 2010
- Primary completion
- Oct 2011
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 2 trial of delafloxacin in community-acquired bacterial pneumonia (CAP), sponsored by Furiex Pharmaceuticals. Started Oct 2010; status: terminated.
02
Drugs
delafloxacin
03
Conditions
community-acquired bacterial pneumonia (CAP)
Beyond the preview
Go deeper on NCT01198626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01198626.